Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Glycogen Phosphorylase Inhibitor N-(3,5-Dimethyl-Benzoyl)-N’-(β-D-Glucopyranosyl)Urea Improves Glucose Tolerance under Normoglycemic and Diabetic Conditions and Rearranges Hepatic Metabolism

Figure 2

Characterization of the in vivo applicability of KB228.

(A) C57/Bl6J male mice (n = 3/3, 3 months of age) were administered KB228, or vehicle (physiological saline, 1% DMSO) i.p., then blood glucose levels were determined using an Accu-Check glucometer (Roche). (B-C) Chow-fed C57/Bl6J male mice (n = 7/7, 6 months of age) were sacrificed 2 hours post treatment with KB228 (90 mg/kg) then (B) glycogen content and (C) the expression the liver, brain and muscle isoforms of GP (pygl, pygb and pygm, respectively) were determined using RT-qPCR. (D-E) HFD-fed C57/Bl6J male mice (n = 9/9, 6 months of age) were sacrificed 2 hours post treatment with KB228 (90 mg/kg) then (D) glycogen content and (E) the expression of the indicated genes were measured by RT-qPCR. * indicate statistically significant difference between vehicle and KB228-treated groups at p<0.05.

Figure 2

doi: https://doi.org/10.1371/journal.pone.0069420.g002